Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.65 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.59 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.59 |
| ▸ | BRAF | P15056 | 9/20 | 0.57 |
| ▸ | CDK1 | P06493 | 2/20 | 0.56 |
| ▸ | CDK2 | P24941 | 2/20 | 0.56 |
| ▸ | DPP4 | P27487 | 1/20 | 0.56 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.56 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.54 |
| ▸ | PRKACA | P17612 | 2/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.51 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3396378 | 0.84 | PDPK1 (0.61) | PDPK1GDABRAFCDK1CDK2 | |
| SCHEMBL29672206 | 0.82 | PDPK1 (0.59) | PDPK1GDABRAFCDK1CDK2 | |
| SCHEMBL2938906 | 0.82 | PDPK1 (0.59) | PDPK1GDABRAFCDK1CDK2 | |
| SCHEMBL16147021 | 0.81 | CDK1 (0.63) | PDPK1GDABRAFCDK1CDK2 | |
| SCHEMBL332978 | 0.81 | BRAF (0.60) | PDPK1GDABRAFCDK1CDK2 | |
| SCHEMBL30523428 | 0.80 | XDH (0.67) | XDHPDPK1GDABRAF | |
| SCHEMBL20565 | 0.80 | XDH (0.67) | XDHPDPK1GDABRAF | |
| SCHEMBL11876697 | 0.80 | XDH (0.67) | XDHBRAFCDK1CDK2CCNB1 | |
| SCHEMBL28457685 | 0.79 | BRAF (0.54) | PDPK1GDABRAFCDK1CDK2 | |
| SCHEMBL16146643 | 0.79 | MGMT (0.55) | PDPK1GDABRAFCDK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1385 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| US-20250297329-A1 | DETECTING BABESIA SPECIES NUCLEIC ACID IN A SAMPLE | GEN PROBE INC (US) | 2025-09-25 | — | — | US | claimed |
| WO-2025024123-A1 | NOVEL CITICOLINE DERIVATIVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-30 | — | — | WO | claimed |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2024-05-02 | — | — | US | claimed |
| EP-4045504-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | Ai-biopharma (FR) | 2022-08-24 | — | — | EP | claimed |
| CN-114901657-A | Antiviral and liver-targeting drugs | 人工智能生物制药公司 | 2022-08-12 | — | — | CN | claimed |
| WO-2021074443-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2021-04-22 | — | — | WO | claimed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | disclosed |
| US-12630820-B2 | Compositions and methods for immunotherapy | INTELLIA THERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12630891-B2 | Compositions and methods for detecting or quantifying hepatitis B virus | GEN-PROBE INCORPORATED (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260132408-A1 | COMPOSITIONS AND METHODS FOR TRANSGENE EXPRESSION FROM AN ALBUMIN LOCUS | INTELLIA THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260132391-A1 | Polynucleotides, Compositions, and Methods for Genome Editing | INTELLIA THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260125690-A1 | COMPOSITIONS AND METHODS FOR TREATING ALPHA-1 ANTITRYPSIN DEFICIENCY | INTELLIA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-0286425-B1 | Therapeutic nucleosides | WELLCOME FOUND (GB) | 1995-01-11 | — | — | EP | disclosed |
| US-5185437-A | 6-substituted 2',3'-dideoxypurine nucleosides; treatment for human immunodeficiency virus and heptatis b virus | BURROUGHS WELLCOME CO. (US) | 1993-02-09 | — | — | US | disclosed |
| US-5068320-A | 2-amino-6-(cyclopropylamino)purine-9-β-D-2',3'-dideoxyribofuranoside and its pharmaceutically acceptable salts | BURROUGHS WELLCOME CO. (US) | 1991-11-26 | — | — | US | disclosed |
| EP-0421819-A1 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-04-10 | — | — | EP | disclosed |
| EP-0417999-A1 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-03-20 | — | — | EP | disclosed |
| EP-0286425-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132391-A1 | Polynucleotides, Compositions, and Methods for Genome Editing | UPF1, RNGTT, NSUN2 | XDH 192/4885PDPK1 4351/4885GDA 120/4885 |
| US-20260132408-A1 | COMPOSITIONS AND METHODS FOR TRANSGENE EXPRESSION FROM AN ALBUMIN LOCUS | METTL16, RNGTT, TRMT1L | XDH 1692/4885PDPK1 4859/4885GDA 605/4885 |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | XDH 253/4885PDPK1 281/4885GDA 1170/4885 |
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | HAVCR2, NR1H4, NR1H3 | XDH 2096/4885PDPK1 4288/4885GDA 4177/4885 |
| US-20260125690-A1 | COMPOSITIONS AND METHODS FOR TREATING ALPHA-1 ANTITRYPSIN DEFICIENCY | SERPINA2, SERPINH1, SERPINE1 | XDH 55/4885PDPK1 4664/4885GDA 1618/4885 |
| US-12630891-B2 | Compositions and methods for detecting or quantifying hepatitis B virus | UPF1, HLA-B, ADAR | XDH 937/4885PDPK1 4735/4885GDA 583/4885 |
| US-12630820-B2 | Compositions and methods for immunotherapy | SPOUT1, HAVCR2, STING1 | XDH 2928/4885PDPK1 4702/4885GDA 1477/4885 |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | SLC10A1, HAVCR2, HDGF | XDH 989/4885PDPK1 1722/4885GDA 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.